First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
The average time of dilation lasts three to eight hours
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Acquisition of exclusive commercialization rights for European markets
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Subscribe To Our Newsletter & Stay Updated
